348 related articles for article (PubMed ID: 37160786)
1. Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy.
Zaitoon H; Lubetzky R; Amir AZ; Moran-Lev H; Sagi L; Yacobi-Bach M; Borger O; Chorna E; Lebenthal Y; Brener A
Acta Diabetol; 2023 Aug; 60(8):1099-1108. PubMed ID: 37160786
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study.
Perna S; Guido D; Bologna C; Solerte SB; Guerriero F; Isu A; Rondanelli M
Aging Clin Exp Res; 2016 Dec; 28(6):1251-1257. PubMed ID: 26749118
[TBL] [Abstract][Full Text] [Related]
3. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS
Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388
[TBL] [Abstract][Full Text] [Related]
4. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
[TBL] [Abstract][Full Text] [Related]
5. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
6. Maturity-Onset diabetes of the young type 5 treated with the glucagon-like peptide-1 receptor agonist: A case report.
Terakawa A; Chujo D; Yasuda K; Ueno K; Nakamura T; Hamano S; Ohsugi M; Tanabe A; Ueki K; Kajio H
Medicine (Baltimore); 2020 Aug; 99(35):e21939. PubMed ID: 32871938
[TBL] [Abstract][Full Text] [Related]
7. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Blazina I; Selph S
Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
[TBL] [Abstract][Full Text] [Related]
8. Semaglutide, A Long-Acting GLP-1 Analogue, for the Management of Early Onset Obesity due to MC4R defect - A Case Report.
Gokul PR; Apperley L; Parkinson J; Clark K; Lund K; Owens M; Senniappan S
Horm Res Paediatr; 2024 Feb; ():. PubMed ID: 38402868
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
10. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes.
Santilli F; Simeone PG; Guagnano MT; Leo M; Maccarone MT; Di Castelnuovo A; Sborgia C; Bonadonna RC; Angelucci E; Federico V; Cianfarani S; Manzoli L; Davì G; Tartaro A; Consoli A
Diabetes Care; 2017 Nov; 40(11):1556-1564. PubMed ID: 28912305
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.
Brady EM; Davies MJ; Gray LJ; Saeed MA; Smith D; Hanif W; Khunti K
Diabetes Obes Metab; 2014 Jun; 16(6):527-36. PubMed ID: 24373063
[TBL] [Abstract][Full Text] [Related]
12. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM; Sofopoulos M; Tsoukas MA; Dincer F; Thakkar B; Sahin-Efe A; Filippaios A; Bowers J; Srnka A; Gavrieli A; Ko BJ; Liakou C; Kanyuch N; Tseleni-Balafouta S; Mantzoros CS
Diabetologia; 2016 May; 59(5):954-65. PubMed ID: 26831302
[TBL] [Abstract][Full Text] [Related]
13. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
[TBL] [Abstract][Full Text] [Related]
14. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.
Cuthbertson DJ; Irwin A; Gardner CJ; Daousi C; Purewal T; Furlong N; Goenka N; Thomas EL; Adams VL; Pushpakom SP; Pirmohamed M; Kemp GJ
PLoS One; 2012; 7(12):e50117. PubMed ID: 23236362
[TBL] [Abstract][Full Text] [Related]
15. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus.
Suzuki D; Toyoda M; Kimura M; Miyauchi M; Yamamoto N; Sato H; Tanaka E; Kuriyama Y; Miyatake H; Abe M; Umezono T; Fukagawa M
Intern Med; 2013; 52(10):1029-34. PubMed ID: 23676586
[TBL] [Abstract][Full Text] [Related]
16. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
[TBL] [Abstract][Full Text] [Related]
17. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
18. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.
Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Pouwels PJ; Pieters-van den Bos IC; Hoekstra T; Diamant M; van Raalte DH; Cahen DL
Diabetologia; 2016 Dec; 59(12):2588-2593. PubMed ID: 27627981
[TBL] [Abstract][Full Text] [Related]
19. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
Moffett RC; Patterson S; Irwin N; Flatt PR
Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
[TBL] [Abstract][Full Text] [Related]
20. Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model.
Fang T; Huang S; Chen Y; Chen Z; Chen J; Hu W
Exp Clin Endocrinol Diabetes; 2021 Sep; 129(9):625-633. PubMed ID: 32961563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
